11.08.16
AMRI
3Q Revenues: $152.7 million (+46%)
3Q Loss: $23.4 million (loss of $4.2 billion 3Q15)
YTD Revenues: $379.1 million (+37%)
YTD Loss: $54.8 million (loss of $4.1 million YTD15)
Comments: Contract revenue was $151.7 million in the quarter, up 50% primarily related to the acquisition of Euticals. Recurring royalty revenue in the quarter was $1.1 million, down from $3.2 million in 3Q15, reflecting a change in estimate of the second quarter royalties related to Allergan's sales of mixed amphetamine salts. R&D expenses in the quarter were $4.6 million, up from $1.9 million in the third quarter 2015, reflecting increased investment in collaboration agreements and API portfolio.
3Q Revenues: $152.7 million (+46%)
3Q Loss: $23.4 million (loss of $4.2 billion 3Q15)
YTD Revenues: $379.1 million (+37%)
YTD Loss: $54.8 million (loss of $4.1 million YTD15)
Comments: Contract revenue was $151.7 million in the quarter, up 50% primarily related to the acquisition of Euticals. Recurring royalty revenue in the quarter was $1.1 million, down from $3.2 million in 3Q15, reflecting a change in estimate of the second quarter royalties related to Allergan's sales of mixed amphetamine salts. R&D expenses in the quarter were $4.6 million, up from $1.9 million in the third quarter 2015, reflecting increased investment in collaboration agreements and API portfolio.
